Form 4: Stryker CLO Robert Fletcher Executes Stock Sale

Stryker Corporation's Chief Legal Officer Robert S. Fletcher sold 4,544 shares of common stock via a pre-arranged 10b5-1 plan.

Summary

• Robert S. Fletcher, VP and Chief Legal Officer of Stryker Corp, sold a total of 4,544 shares of common stock on May 28, 2026.
• The transactions were executed at weighted average prices ranging from $304.225 to $310.22 per share.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 26, 2026.
• Following these transactions, the reporting person retains direct ownership of 10,582 shares and indirect ownership of 183 shares via a 401(k) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-established, automated trading plan, which is standard practice for corporate executives.

Positives

• The sale was executed under a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• None identified; this is a routine disclosure of executive equity transactions.

Future Outlook

No forward-looking guidance or operational outlook provided in this document.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are common in the medical technology sector and generally do not signal a change in corporate strategy or performance outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers at large-cap companies like Stryker to manage personal liquidity.
• The volume of shares sold is consistent with typical executive portfolio rebalancing for a company of Stryker's market capitalization.

Stakeholder Impact

• Minimal impact expected as the sale was executed via a pre-planned, non-discretionary trading program.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Stryker, SYK, Insider Trading, Form 4, Executive Compensation, Equity Sale